Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Candle stick who wrote (745)	9/22/1998 8:37:00 PM
From: Hong-Lee Yu	Read Replies (1) \| Respond to of 1686

Candle stick, I won't be selling before Q3 report. The entire biotech sector is rallying. The EPS estimate for Q3 has been raised to 0.49C to 0.46C. I do think they are going to beat the revised earning again. The real interesting one to find out is the trend of Avonex sales. Why can they add another 5000 patients in Q3 (slowest season). Can we assume this going forward ? If answer is yes, EPS for 99' will be well over 2.50. Analysts will be forced to raise the target price again. Any positive news on the pipelines will allow analysts to assign a higher multiple (currently 30) to BGEN.